课题基金 / 基金详情

项目摘要

项目成果

MAARTEN G LANSBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Currently, the only FDA approved treatment for acute stroke is intravenous tissue plasminogen activator (iv tPA) administered within three hours after symptom onset. Only three percent of stroke patients in the United States receive iv tPA, because most patients present to the hospital beyond the three hour time-limit for iv tPA. Although clinical trials have not demonstrated benefit from iv tPA beyond three hours, a subgroup of stroke patients who benefit is likely to exist. This subgroup needs to be identified in order to increase the proportion of stroke patients who may be treated with tPA. The candidate proposes, in three Specific Aims, to investigate whether 1) clinical, 2) computed tomography (CT) and 3) magnetic resonance imaging (MRI) characteristics help identify patients who are most likely to have a favorable response to iv tPA in the three to six hour time-window. Based on the results of these projects, the candidate intents to develop a practical clinical prediction tool, which will enable physicians to stratify acute stroke patients and identify those who are most likely to have a favorable response to tPA. Dr. Lansberg is completing his Cerebrovascular Fellowship at Stanford University Medical Center and he will join the staff of the Department of Neurology and Neurological Sciences at Stanford University on July 1, 2004. His career goal is to improve the health of stroke patients through clinical research and direct patient care. His career development plan combines a highly relevant clinical research proposal with complementary didactic training. He will complete a Master of Science Program in Clinical Epidemiology and Biostatistics and he will get training in MRI technology. The candidate has a team of mentors who are world-renowned researchers in the following four fields: Clinical studies of acute stroke, neuroradiology, MRI physics and biostatistics. They will provide guidance throughout the award period and facilitate his transition into a successful independent investigator.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1161/strokeaha.109.552547
发表时间: 2009-07
期刊: Stroke
影响因子: 8.3
作者: [Lansberg MG, Bluhmki E, Thijs VN]
通讯作者: Thijs VN
DOI: 10.1016/s1474-4422(12)70203-x
发表时间: 2012-10
期刊: The Lancet. Neurology
影响因子: --
作者: [Lansberg MG, Straka M, Kemp S, Mlynash M, Wechsler LR, Jovin TG, Wilder MJ, Lutsep HL, Czartoski TJ, Bernstein RA, Chang CW, Warach S, Fazekas F, Inoue M, Tipirneni A, Hamilton SA, Zaharchuk G, Marks MP, Bammer R, Albers GW, DEFUSE 2 study investigators]
通讯作者: DEFUSE 2 study investigators
DOI: 10.1161/strokeaha.111.615682
发表时间: 2011-08
期刊: Stroke
影响因子: 8.3
作者: [Tung CE, Win SS, Lansberg MG]
通讯作者: Lansberg MG
DOI: 10.1016/j.jstrokecerebrovasdis.2008.03.005
发表时间: 2008-07
期刊: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
影响因子: --
作者: [M. Lansberg]
通讯作者: M. Lansberg
ARCADIA CSI (Cognition and Silent Infarcts)
  • 批准号:
    10207805
  • 项目类别:
  • 资助金额:
    $160.91万
  • 财政年份:
    2019
  • 负责人:
    MAARTEN G LANSBERG
  • 依托单位:
ARCADIA CSI (Cognition and Silent Infarcts)
  • 批准号:
    10450768
  • 项目类别:
  • 资助金额:
    $20.86万
  • 财政年份:
    2019
  • 负责人:
    MAARTEN G LANSBERG
  • 依托单位:
CTP to predict Response to recanalization in Ischemic Stroke Project (CRISP)
  • 批准号:
    8431810
  • 项目类别:
  • 资助金额:
    $56.13万
  • 财政年份:
    2011
  • 负责人:
    MAARTEN G LANSBERG
  • 依托单位:
CTP to predict Response to recanalization in Ischemic Stroke Project (CRISP)
  • 批准号:
    8246275
  • 项目类别:
  • 资助金额:
    $62.75万
  • 财政年份:
    2011
  • 负责人:
    MAARTEN G LANSBERG
  • 依托单位:
海外基金